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ΠΕΡΙΛΗΨΗ 
Εισαγωγή: Ο θεμέλιος λίθος της τρέχουσας θεραπευτικής αγωγής για τη 
νεοαγγειακή Εκφύλιση της Ωχράς Κηλίδας είναι η θεραπεία με φάρμακα αντι-
Αγγειακού Ενδοθηλιακού Αυξητικού Παράγοντα. Συστηματικές 
Ανασκοπήσεις(ΣΑ) και Μετα-αναλύσεις(ΜΑ) στοχεύουν στην 
αποτελεσματικότητα και την ασφάλεια της εξιδρωματικής ΗΕΩ θεραπείας. 
Στόχοι: Να αξιολογηθεί η ποιότητα αναφοράς Μετα-αναλύσεων στην θεραπευτική 
αντιμετώπιση και ασφάλεια για τη νεοαγγειακή ΗΕΩ με βάση το PRISMA 
Statement. 
Μέθοδοι: Ηλεκτρονική αναζήτηση πραγματοποιήθηκε τον Αύγουστο του 2018 
ώστε να βρεθούν οι δημοσιευμένες μετα-αναλύσεις από τον Απρίλιο 2014 έως το 
Μάιο του 2018. Η αξιολόγηση πραγματοποιήθηκε με βαθμολογήσεις του 
PRISMA checklist για καθεμία μετα-ανάλυση και για κάθε PRISMA θέμα. Η 
στατιστική ανάλυση των χαρακτηριστικών που επηρεάζουν την ποιότητα 
αναφοράς εμπεριέχει ανάλυση πολυμεταβλητότητας σε υπο-ομάδες και ανάλυση 
συσχέτισης.  
Αποτελέσματα: Δώδεκα μετα-αναλύσεις συμπεριλήφθηκαν τελικά, τρεις ούσες 
Cochrane ΣΑ. Η μέση PRISMA βαθμολόγηση είναι 23,2/27(86,1%). Έντεκα 
PRISMA θέματα είχαν σημαντικά υψηλότερη εκατοστιαία βαθμολογία σε δώδεκα 
ΜΑ από εκείνη σε εννέα ΜΑ. Θετική ισχυρή συσχέτιση παρουσιάζεται ανάμεσα 
στην εκατοστιαία βαθμολόγηση και το συντελεστή απήχησης περιοδικού. Η 
ανάλυση πολυμεταβλητότητας μεταξύ υψηλόβαθμες και χαμηλόβαθμες Μετα-
αναλύσεις ανέδειξε συσχέτιση με αρκετές παραμέτρους (π.χ. συντελεστή 
απήχησης, ημερομηνία δημοσίευσης).  
Συμπέρασμα: Γενικά, η αξιολόγηση της ποιότητας αναφοράς ήταν ευνοϊκή. Όπως 
αναμενόταν, ο ρόλος-κλειδί των διαφόρων χαρακτηριστικών των μετα-
αναλύσεων μπορεί να επηρεάσει την ποιότητα αναφοράς. Η έλλειψη αναφοράς 
συγκεκριμένων θεμάτων (πρωτόκολλο, στρατηγική αναζήτησης, αξιολόγηση 
σφαλμάτων) δηλώνει την επιτακτικότητα για συμμόρφωση στο PRISMA 
statement. 
Λέξεις-κλειδιά: PRISMA, ΗΕΩ, ποιότητα αναφοράς, μετα-ανάλυση, συστηματική ανασκόπηση, 
αντι-Αγγειακού Ενδοθηλιακού Αυξητικού Παράγοντα,  
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ABSTRACT 
Background: The cornerstone of current treatment strategy of Neovascular Age-
related Macular Degeneration is anti-VEGF therapy. Systematic Reviews(SRs) 
and Meta-analyses(MAs) are targeted on the efficacy and safety of exudative-
AMD treatment.  
Objective: To evaluate the reporting quality of meta-analysis on neovascular 
AMD treatment and safety profile based on PRISMA statement. 
Methods: Electronic search performed in August 2018 to retrieve meta-analyses 
published from April 2014 to May 2018. PRISMA evaluation was determined by 
total scores of individual MAs and items scores. Statistical analysis of parameters 
affecting the reporting evaluation included subgroup multivariate analysis and 
regression analysis.  
Results: Twelve meta-analyses were finally included, three being Cochrane SRs. 
Mean PRISMA score is 23,2/27 (86,1%). Eleven PRISMA ITEMS had 
significantly higher %score in 12 MAs than in 9 non-Cochrane MAs 
measurements. Positive strong correlation identified between PRISMA %score 
and Journal Impact Factor(JIF) . Multivariate analysis between high-scored and 
low-scored MAs established difference in means of several parameters 
(JIF,Publication Year).   
Conclusions: The evaluation of overall reporting quality was favorable. As 
expected, the key role of several characteristics of meta-analysis affects this 
quality.  Under-reporting of specific items (protocol, search strategy and 
assessment of risk of bias) indicate the urgency for PRISMA compliance. 
Keywords: PRISMA, AMD, anti-VEGF, reporting quality, meta-analysis, 
systematic reviews 
 
Introduction 
Age-related macular degeneration treatment trends: Age-related macular 
degeneration (AMD) is numbered among the leading causes of visual impairment 
in developed countries. After cataract and glaucoma, it is considered a major 
cause of visual loss and blindness globally (1-3). AMD is a chronic degenerative 
disease of the central part of the retina, including the macular area. Having an 
unfavorable progression, it can lead to visual impairment and in serious cases it 
is responsible for central blindness. In most cases, central vision lost by AMD is 
largely irreversible and has a tremendous impact on the patient’s life. As a result 
of increasing aging of the population worldwide, this impact will continue to affect 
more elderly individuals. AMD affects more than 1.75 million individuals in the 
United States and the prediction estimates that this number will raise to 3 million 
by 2020 (3). Two different clinical types of the disease present with different 
clinical manifestations: the non-neovascular (dry) type and the neovascular (wet) 
type, which leads to approximately 90% of devastating visual losses due to both 
these types (4). The treatment strategies against neovascular AMD’s pernicious 
progression changed by the introduction of Anti-Vascular Endothelial Growth 
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Factor (anti-VEGF) agents. Previous treatment strategies included mainly 
PhotoDynamic Therapy (PDT). VEGF-A is found to promote angiogenesis and 
choroidal neovascularization (CNV) (5). A new era has begun in the treating 
options for patients having exudative-AMD since the approval of ranibizumab by 
the Food and Drug Administration (FDA) in the US in 2006. The European 
Agency for the Evaluation of Medicinal Products (EMEA) also approved 
ranibizumab for AMD treatment in 2007. Many other countries across the world 
have later approved ranibizumab, for example Japan in 2009. Ranibizumab 
(Lucentis, Genentech, Inc., South San Francisco, CA, USA) was not the first anti-
VEFG agent to be used in AMD therapy by intravitreal injections. Pegaptanib 
(Macugen Eyetech Inc., Palm Beach Gardens, FL, USA) was the initial anti-
VEGF drug in use from 2004, although it was later abandoned due to visual 
deterioration (6-7).  Pegaptanib’s breakthrough is not forgotten, since it opened a 
new horizon in not only the understanding of pathophysiology but also a new 
therapeutic perspective in a previously regarded field with limited treatment 
future. An off-label used anti-VEGF agent is bevacizumab (Avastin, Genentech, 
Inc., South San Francisco, CA, USA/Hoffmann-La Roche Ltd., Basel, Switzerland 
first used off-label in 2005). Bevacizumab was approved by the FDA in 2004 for 
the treatment of metastatic cancer of the colon, but did not gain approval for 
intravitreal injections so far. Its low cost is a major advantage versus ranibizumab 
(8). Nevertheless, research has emerged considerations about bevacizumab’s 
systemic safety profile. In 2011, US Food and Drug Administration approved 
another anti-VEGF agent, aflibercept (VEGF Trap-Eye, Eylea, Regeron, 
Tarrytown, New York, USA) for the treatment of neovascular AMD (9). Longer 
half-life of aflibercept and increased binding affinity has increased expectations in 
number retreatments needed in AMD therapeutic challenge. To our most recent 
knowledge, conbercept, an additional anti-VEGF Trap-Eye, was approved by the 
China Food and Drug Administration to be added to treatment options for 
neovascular AMD in China ((also named KH902, Chengdu Kanghong Biotech 
Co., Ltd., Sichuan, China) (10). Nowadays, three agents are the cornerstone of 
wet-AMD treatment: bevacizumab, ranibizumab and aflibercept. 
Key purpose of Meta-analysis: Systematic reviews (SRs) and meta-analysis 
(MAs) are at the top of the pyramid describing the validity and importance of 
Evidence-Based Medicine. High-level information and evidence about the effects 
of interventions and healthcare decisions are presented in systematic reviews 
and meta-analysis. An extremely important effort is made to gather results from 
studies and through complex and detailed analysis to provide recommendations 
and guidelines on clinical practice. Reviewers can methodologically handle data 
from studies to summarized pooled effect estimates. By this procedure called 
meta-analysis, the review authors can demonstrate a pooled and overall effect of 
all clinical research performed on a certain field of interest. Meta-analysis major 
use is to draw conclusions on the topic under investigation by integrating certain 
numerical data from independent studies, according to their weighted 
measurement. Meta-analyses are the most popular citated forms of clinical 
research (11). They represent the quantitative form of systematic reviews aiming 
to determine a more precise effect of the treatment or any specific research 
theme. Glass was the first author to define meta-analysis as ‘the statistical 
analysis of a large collection of analysis results from individual studies for the 
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purpose of integrating the findings in 1976 (12). The source of aggregated data is 
mostly derived from Randomized Controlled Trials (RCTs), although other study 
designs, such as observational studies, have been included in meta-analytic 
assessments. Nonrandomized studies have a tendency to result into large 
treatment effects, thus leading to contradictory meta-analytic pooled effects (13). 
When conducting a meta-analysis, authors should scrutinize their explicit 
methodological strategies step-by-step. Ideally, a protocol should be followed. 
Being more valuable than any study, meta-analysis can be susceptible to 
different kinds of biases, for example publication bias and selective reporting bias 
(14). Time lag bias and language bias have also been reported to affect the 
estimated results of a meta-analysis (15,16).  
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
statement: The foremost consulting paper for the proper conduct of meta-
analysis was published by Cochrane Collaboration and consists of specific 
guidelines to be attended by reviewers performing SRs and MAs (17). In 2009, 
the same year the Cochrane Handbook was published, another guidance tool 
was available called the Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA) statement. (18). The PRISMA statement is considered 
an indispensable tool to be used in order to facilitate the transparent 
demonstration of information in a systematic review or meta-analysis. Adequate 
information should be reported in an unambiguous way in aim of readers to 
understand the merits and the limitations of a research effort in a published 
paper. PRISMA statement is the updated guidance tool of the QUOROM (Quality 
Of Reporting Of Meta-analysis) (19). The QUOROM statement was published in 
1999, but further need for improving reporting of collation of evidence and the 
expanding accumulation of knowledge on the proper methodological conduct of 
clinical trials resulted in the broader and more detailed PRISMA statement. It 
includes 27 items in a checklist and a four-phase flow diagram. Furthermore, 
PRISMA statement is accompanied by an Explanation and Elaboration document 
assisting authors, readers and editors in comprehending each reporting item 
independently by fully describing the meaning of each item and by presenting an 
example (20). The PRISMA checklist and additional document is available and 
downloadable to facilitate any researcher in order to endorse this valuable 
statement in clearly presenting a systematic review or meta-analysis. PRISMA 
statement’s major scope is to provide all key characteristics that should be 
systematically and transparently presented and described in a meta-analysis to 
enlarge its potential utility in medicinal practice. Furthermore, the scrutinized 
specification of information included in a meta-analysis raises the possibility for 
expanded applicability of the results provided by the analysis. 
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Objectives  
In this task, we aim to assess the reporting quality of Meta-analysis of 
Randomized Controlled Trials using the PRISMA statement as a guidance and 
recommendation tool. Our goal is to investigate whether meta-analysis in this 
research area has supported the use of PRISMA checklist in presenting 
accurately what they did and how they did it. This task is restricted to meta-
analysis and consequently, it does not include simply systematic reviews without 
quantitative analysis. Moreover, the only design type of studies included in each 
meta-analysis is Randomized Controlled Trials. The reporting quality of the meta-
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analyses in this assessment is to be inspected by PRISMA scoring and statistical 
analysis.  
Eligibility criteria  
All included meta-analysis in this task had to fulfill clearly the below criteria: 
 They should contain quantitative analysis (i.e. meta-analysis) and not only 
qualitative results. 
 The studies analyzed should be only Randomized Controlled Trials 
(RCTs). 
 The participants’ cause of choroidal neovascularization should be 
neovascular Age-related Macular Degeneration, not other degenerative 
diseases of the retina, such as polypoidal choroidal vasculopathy. 
 The meta-analysis included should investigate topics that refer to 
neovascular AMD therapeutic approaches and/or the safety profile of 
these approaches. 
 The meta-analysis should be published from April, 1st in 2014 to May, 31ST 
in 2018. 
Exclusion criteria 
 Any other study design type, for example retrospective studies, preclinical 
studies, cohort studies, case cohort studies.  
 Any other topic relevant to AMD, but not relevant to therapeutic 
effectiveness or ocular/systemic safety of exudative AMD treatment, such 
as prevalence and incidence of AMD, genetic polymorphisms, risk factors 
and biomarkers, pathogenetic issues, diagnostic methods. 
 Any other cause of choroidal neovascularization, for example myopia, 
uveitis or other degenerative disease. 
 Any systematic review that does not contain meta-analytic assessment. 
 Any deviation from the dates of publication mentioned (April 2014 to May 
2018. 
Literature search 
We searched the Cochrane Database of Systematic Reviews (from inception to 
August 2018), PubMed (from January 2014 to September 2018), Scopus (from 
January 2014 to August 2018 limited to Open Access and Medicine applications) 
and EMBASE databases. We also searched other electronic sources, such as 
Open Science Directory and Directory of Open Access Journals in an effort to 
identify additional articles. Only articles in the English language were assessed 
for eligibility. May 31st, 2018 was the last date searched.  
Data extraction Process and Search Results 
A systematic literature search was performed in the above electronic data 
sources (PubMed, CDSR, Scopus, EMBASE) and data were screened by title 
and summary. Date filters were applied in both PubMed and Scopus databases. 
Overall, 210 articles were extracted and after duplicates removed, 119 articles 
were screened. Additionally, data extracted from Open Science Directory and 
Directory of Open Access Journals were also screened for eligibility (42 articles) 
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and all of them excluded, as they were either duplicates or irrelevant. The initial 
search terms involved: ‘AMD’, ‘ AMD treatment’, ‘macular degeneration’, 
‘neovascular age-related macular degeneration’, ‘anti-VEGF’, ‘anti-vascular 
endothelial growth factor’, ‘Ranibizumab OR Lucentis’, ‘Bevacizumab OR 
Avastin’, ‘Pegaptanib OR Macugen’, ‘Aflibercept OR Eylea’, ‘anti-VEGF safety’, 
‘meta-analysis’ and ‘systematic review’. The following information was extracted 
from each article: title, first author, year of publication, abstract. 84 records were 
excluded, predominantly due to irrelevant theme of interest, and 35 full text 
articles were evaluated thoroughly according to fulfillment of eligibility criteria. 
The majority of the excluded full-text articles contained other types of study 
design. Finally, twelve meta-analyses were assessed, three being Cochrane 
Systematic Reviews (21-32). Four-phase flow diagram is summarizing this 
process. 
 
PRISMA 2009 Flow Diagram 
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Methods  
The 27-item checklist of PRISMA was determined for each meta-analysis. The 
score assigned to each item was either 0 or 1, with equal weight. Zero represents 
the lack of adequate reporting and 1 was assigned to papers that the reporting 
was sufficiently accurate. The total highest score is 27/27(100%) and the total 
minimum score is 0/27(0%). We decided on simplifications for clarified 
explanation on this assessment. For ITEM №4, if the authors did not report 
specific objectives according to the PICOS approach, but it was clarified through 
the information across the article, the evaluation was 1. For ITEM №5, if there 
was report of a registration number but no protocol, the item’s evaluation was 0. 
For ITEMS concerning the risk of bias assessment, if the authors reported only 
quality assessment with a cumulative score, for example Jadad score, the items 
were scored 0. For ITEM №27, if support was mentioned in general rather than a 
specific funding source, the item’s evaluation was 0. PRISMA ITEMS score was 
calculated as percentage of evaluations for individual items. Data were analyzed 
by statistical package SPSS (IBM SPSS statistics 23.0). Level of statistical 
significance threshold was a Pvalue of 0,05, except for linearity threshold set at 
0,001. Pearson correlation ‘r’ was calculated for investigation of correlation 
between PRISMA evaluation and other variables, e.g. journal impact factor. 
Subgroup multivariate analysis was conducted to identify possible difference 
between meta-analyses assigned to high PRISMA score (≥24/27) and meta-
analyses assigned to lower PRISMA score (≤23/27) in simultaneous evidence 
from dependent characteristics. Multivariate analysis was also performed 
between meta-analyses with and without claim of PRISMA adherence in 
accumulated evidence from characteristic measurements. Lastly, secondary 
outcomes analysis used multivariate analysis and chi-square test. Chi-square 
test was used in aim to detect difference in proportions of meta-analyses with 
high and low PRISMA score in the usage of different guidance tools for bias 
estimates. 
Characteristics of the Meta-analyses included 
The meta-analyses characteristics are displayed in Tables 1 and 2. Five meta-
analyses were conducted according to PRISMA guidance. All papers included 
RCTs only, with the exception of Li S et al (22) including 4 RCTs and 2 quasi-
RCTs in their analysis. The number of studies included in the MAs ranged from 2 
(Sarwar S) to 15 (Nguyen CL). The mean number of studies was 8,2. Four out of 
twelve MAs included >10 RCTs (33,3%). Similarly, three out of 9 non-Cochrane 
MAs included >10 RCTs (33,3%) (Nguyen CL, Ba J, Ueta T). According to year 
of publication, 6 out of 12 papers were published in 2014 (50%). Also, three MAs 
were published in 2017 and 2018 (23%). Journal impact factors (JIFs) ranged 
from 0,705 (Si JK) to 6,135 (Ueta T). Mean JIF among meta-analyses was 3,471. 
The highest impact factors were possessed by Ophthalmology and Cochrane 
Collaboration. Mean number of authors was 7,2. Eight MAs used the Cochrane 
Handbook of Systematic Reviews of Interventions as a tool for quality and risk of 
bias evaluation and four MAs used Jadad score or author’s opinion. All papers 
presented the four-phase flow diagram and 6 out of the 9 non-Cochrane reviews 
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presented the reasons of excluding studies on the flow diagram. However, in 
Ueta et al meta-analysis (28) the type of the flow diagram was not the typical 
four-phase.  
 
Primary outcomes 
1. Scoring: compliance to PRISMA statement measured by PRISMA score 
(proportion and percentage) for individual meta-analyses based on the 
evaluation of each meta-analysis. Also, PRISMA ITEMS percentage score 
for individual items based on the evaluation of the cumulative score of 
meta-analyses.  
2. Comparison between all 12 MAs and 9 non-Cochrane MAs in mean 
difference of PRISMA ITEMS percentage score.  
3. Correlation between PRISMA percentage score in individual meta-analysis 
and year of publication, number of authors, number of studies, number of 
patients and journal impact factor. If detected, investigation of the possible 
linear correlation.  
4. Subgroup comparison between MAs with PRISMA score ≤23/27 and MAs 
with PRISMA score ≥24/27 in accumulated evidence from the mean 
values of: number of authors, number of studies, number of patients, year 
of publication and impact factor by multivariate analysis. 
 
Secondary outcomes 
1. Comparison between MAs with PRISMA endorsement and MAs without 
PRISMA endorsement in mean difference of PRISMA percentage score. 
2. Subgroup comparison between MAs with PRISMA endorsement and MAs 
without PRISMA endorsement in accumulated evidence from the mean 
values of: PRISMA percentage score, number of authors, number of 
studies, number of patients, year of publication and impact factor by 
multivariate analysis.  
3. Comparison between MAs using Cochrane Handbook of Systematic 
Reviews of Interventions as a guidance tool for risk of bias assessment 
and MAs using Jadad score or author’s opinion in mean difference of 
PRISMA percentage score. 
4. Subgroup comparison between the MAs using the Cochrane Handbook of 
Systematic Reviews of Interventions for risk of bias assessment and the 
MAs using Jadad score or author’s opinion in the accumulated evidence 
from the mean values of: PRISMA percentage score, number of authors, 
number of studies, number of patients, year of publication and impact 
factor by multivariate analysis.  
5. Comparison of the proportions of MAs with PRISMA score ≤23/27 and the 
MAs with PRISMA score ≥24/27 in the usage of different guidance tools 
for risk of bias assessment (either Cochrane Handbook of Systematic 
Reviews of Interventions or Jadad score/author’s opinion)  
Results  
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Primary results 
 
Results of PRISMA ITEMS scoring: PRISMA ITEMS percentage score in all 12 
meta-analyses and in 9 non-Cochrane meta-analyses are presented in Table 3 
and they are demonstrated visually in Simple Bar Charts (Figures 1 and 2). 
Sixteen PRISMA ITEMS were 100% reported. In 12 MAs, ITEM №5:Protocol and 
Registration (41,6%), ITEM №8:Electronic Search Strategy (41,6%), ITEM 
№27:Funding (41,6%) and ITEM №12:Methods of Risk of Bias in individual 
studies (58,3%) were the least reported items, to be followed by ITEM №15:Risk  
of Bias across studies (66,6%) and ITEM №22:Results of Risk of Bias across 
studies (66.6%). These results are prominently lower in the nine non-Cochrane 
subgroup. 
Table 1: Meta-Analyses Characteristics 
 
 
 
 META-
ANALYSIS 
№ of 
AUTH
ORS 
№ of 
STUD
IES 
STUDY 
DESIGN 
№ of 
PATIE
NTS 
Tool for Quality 
and Risk of bias 
Assessment 
Quality  
1 Nguyen CL 5 15 RCT 8320 Cochrane Handbook of 
Systematic Reviews of 
Interventions 
High 
2 Li S 5 6 RCT and 
quasi-RCT 
278 Cochrane Handbook of 
Systematic Reviews of 
Interventions 
Moderate 
3 Tong Y 7 8 RCT 800 Author’s Opinion Judgment 
Missing 
4 Ba J 7 12 RCT 5225 Jadad score Moderate 
5 Wang W 2 ⁴44       4 RCT 2613 Jadad score High 
6 Kodjikian 
L 
7 5 RCT 2686 Cochrane Handbook of 
Systematic Reviews of 
Interventions 
Low 
7 Si JK 10 7 RCT 742 Jadad score High 
8 Ueta T 5 11 RCT 6596 Cochrane Handbook of 
Systematic Reviews of 
Interventions +MedRA 
classification of adverse 
events 
Moderate 
9 Su Y 3 8 RCT 817 Cochrane Handbook of 
Systematic Reviews of 
Interventions 
Moderate 
10 Sarwar S 10 2 RCT 2457 Cochrane Handbook of 
Systematic Reviews of 
Interventions + GRADE 
High 
11 Moja L 21 9 RCT 3665 Cochrane Handbook of 
Systematic Reviews of 
Interventions +  MedRA 
classification of adverse 
events 
Moderate 
12 Solomon 
SD 
 
5 12 RCT 5496 Cochrane Handbook of 
Systematic Reviews of 
Interventions 
High 
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Table 2: Meta-Analyses Characteristics (continue) 
 
 
   № META-ANALYSIS Year of 
publicati
on 
Journal Impact 
Factor for 
the year 
Primary Outcome Other Outcomes 
1 Nguyen CL 
 
2018 BMC Ophthalmology 1,770 Anti-VEGF agents: mean 
change in BCVA  
Anti-VEGF agents: mean change 
in CRT, Safety RRs 
2 Li S 
 
2017 PLoS One 2,776 Topical NSAIDS and anti-
VEGF vs anti-VEGF: mean 
change in BCVA 
Topical NSAIDS and anti-VEGF vs 
anti-VEGF: mean change in CRT 
and injection number, ORs for 4 
adverse events 
3 Tong Y 
 
2016 International Journal of 
Ophthalmology 
1,177 PDT and anti-VEGF vs  anti-
VEGF: mean change in 
BCVA 
PDT and anti-VEGF vs  anti-VEGF: 
mean change in CRT and BCVA 
more than 15,10,5 or 0 letters 
and injection number 
4 Ba J 
 
2015 Drug Design 
Development and 
Therapy 
2,881 Anti-VEGF agents: mean 
change in BCVA 
Anti-VEGF agents: mean change 
in CRT, lesion size, BCVA change 
in different regimens 
5 Wang W 2014 PLoS One 3,234 Anti-VEGF agents 
(ranibizumab vs 
bevacizumab): safety RRs 
for death from all causes 
Anti-VEGF agents (ranibizumab vs 
bevacizumab): safety RRs for 
arteriothrombotic events, stroke, 
MI, venous thrombosis and 
hypertension 
6 Kodjikian L 
 
2014 Graefes Archive for 
Clinical and 
Experimental 
Ophthalmology 
1,908 Anti-VEGF agents 
(ranibizumab vs 
bevacizumab): mean 
change in BCVA 
Anti-VEGF agents (ranibizumab vs 
bevacizumab):  mean change in 
CRT and ORs for systemic adverse 
events 
7 Si JK 
 
2014 International Journal of 
Ophthalmology 
0,705 PDT and ranibizumab vs 
ranibizumab:  mean 
change in BCVA 
PDT and ranibizumab vs 
ranibizumab:  mean change in 
CRT and BCVA gaining more than 
3 and 0 lines, injection number, 
safety for four adverse events 
8 Ueta T 
 
2014 Ophthalmology 6,135 Ranibizumab regimen 
monthly vs PRN, 0,5mg vs 
0,3mg, 0,3mg vs 0,0mg: 
mean change in 
cerebrovascular accidents, 
MI, non-ocular 
hemorrhage 
Ranibizumab regimen o,5/0,3mg 
vs 0,0, 0,5mg vs 0,3/0,0mg, 
monthly vs PRN/control: mean 
change in cerebrovascular 
accidents, MI, non-ocular 
hemorrhage 
9 Su Y 
 
2018 Photodiagnosis and 
Photodynamic Therapy 
2,895 PDT and ranibizumab vs 
ranibizumab:  mean 
change in BCVA 
PDT and ranibizumab vs 
ranibizumab: ):  mean change in 
CRT, LS, injection number, 
proportion of patients gaining 
>15 letters, proportion of 
patients losing >15 letters, RR of 
adverse events 
10 Sarwar S 2016 Cochrane Database of 
Systematic Reviews 
6,124 Aflibercept vs 
ranibizumab, 
bevacizumab, or sham: 
mean change in BCVA 
outcomes 
Aflibercept vs ranibizumab, 
bevacizumab, or sham: mean 
change in morphological 
outcomes, safety outcomes, 
quality-of life outcomes, mean 
number of injections 
11 Moja L 2014 Cochrane Database of 
Systematic Reviews 
6,032 Bevacizumab versus 
ranibizumab : safety RRs 
for death and all SSAEs 
Bevacizumab versus ranibizumab 
: safety RRs for different SSAEs in 
MedRA SOC classification 
12 Solomon SD 
 
2014 Cochrane Database of 
Systematic Reviews 
6,032 Anti-VEGF agents: mean 
change in BCVA outcomes 
Anti-VEGF agents: mean change 
in morphological outcomes, 
BCVA outcomes, quality-of-life, 
ocular or systemic adverse 
events, economic data outcomes 
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Table 3: PRISMA ITEMS percentage score in 12 MAs and 9 MAs 
 
 
     
SECTION № PRISMA Item 
(definition) 
% Percentage 
of Total score 
in 12 MAs 
% Percentage of Total 
score in 9 MAs (Cochrane 
excluded) 
TITLE 1 Title 100 100 
ABSTRACT 2 Structured Summary 91,6 88,8 
INTRODUCTION 3 Rationale 100 100 
 4 Objectives 100 100 
METHODS 5 Protocol & Registration 41,6 22,2 
 6 Eligibility Criteria 91,6 88,8 
 7 Information Sources 100 100 
 8 Search Strategy 41,6 22,2 
 9 Study Selection 100 100 
 10 Data collection progress 75,0 66,6 
 11 Data Items 100 100 
 12 Methods for Risk of Bias in 
individual studies 
58,3 44,4 
 13 Summary Measures 100 100 
 14 Synthesis of Results 100 100 
 15 Risk of Bias across studies 66,6 55,5 
 16 Additional Analysis 100 100 
RESULTS 17 Study Selection 100 100 
 18 Study Characteristics 100 100 
 19 Results on Risk of Bias in 
individual studies 
75,0 44,4 
 20 Results of Individuals 
studies 
100 100 
 21 Synthesis of Results 100 100 
 22 Results of Risk of Bias 
across studies 
66,6 55,5 
 23 Additional Analysis Results 100 100 
DISCUSSION 24 Summary Evidence 100 100 
 25 Limitations 100 100 
 26 Conclusions 91,6 88,8 
FUNDING 27 Funding 41,6 22,2 
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Results of PRISMA scoring in individual meta-analyses: All 3 Cochrane MAs 
(Sarwar CL et al, Moja L et al, Solomon SD et al) were assessed with the highest 
PRISMA score 27/27 (100%). The remaining meta-analyses score ranged from 
19/27 (70,3%) to 26/27 reported items (96,2%). The mean PRISMA score is 
23,2/27 (86,1%) for all 12 MAs. Excluding Cochrane MAs, the mean PRISMA 
score for 9 MAs changes to 22/27 (81,4%). PRISMA statement was claimed to 
be endorsed by 5 out of 12 papers and by 5 out of 9 non-Cochrane MAs. The 
mean PRISMA score in the above five MAs was 22,2/27. The results of scoring 
are displayed in Table 4. 
 
 
Figure 1: Simple Bar Chart of PRISMA items score in 12 meta-analyses 
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Figure 2: Simple Bar Chart of PRISMA items score in 9 non-Cochrane meta-analyses 
Results of difference in means of PRISMA ITEMS percentage score between all 
12 MAs and 9 non-Cochrane MAs:  
In order to detect the possible difference in means of PRISMA ITEMS %score, 
we decided to distinguish between the score of items from all 12 MAs and the 
score of items after the exclusion of Cochrane Systematic Reviews (Sarwar S, 
Moja L, Solomon SD). Normality distribution test demonstrated negative results 
(Pvalue=0,000<0,05 in Shapiro-Wilk and Kolmogorov-Smirnoff), stating the need 
for performing non-parametric Wilcoxon test. Wilcoxon test was statistically 
significant (Pvalue=0,003<0,05), as shown in SPSS Figures 1,2 and 3. We 
concluded that there is evidence of difference in mean percentage score of 
PRISMA ITEMS. In fact, in 11 PRISMA ITEMS the %score was higher in 12 MA 
measurements than in 9 non-Cochrane measurements. In 0 ITEMS, no 
difference was detected. The results of the descriptives are also presented 
below. The mean % score of PRISMA ITEMS in 12 meta-analyses is 87,1% and 
in 9 meta-analyses is 81,4%. The inclusion of 3 Cochrane Systematic Reviews in 
this assessment raised significantly the results of 11 PRISMA ITEMS percentage 
score.  
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Table 4: PRISMA score in individual meta-analyses included 
 
 
 
 
SPSS Figures 1, 2 and 3: Primary Results 
 
 
 META-
ANALYSIS 
PRISMA 
SCORE 
% PRISMA 
ENDORSEMENT 
1 Nguyen CL 
 
25/27 92,5 NO 
2 Li S 
 
24/27 88,8 YES 
3 Tong Y 
 
19/27 70,3 NO 
4 Ba J 
 
19/27 70,3 NO 
5 Wang W 20/27 74,0 YES 
6 Kodjikian L 
 
22/27 81,4 YES 
7 Si JK 
 
19/27 70,3 YES 
8 Ueta T 
 
26/27 96,2 YES 
9 Su Y 
 
24/27 88,8 NO 
10 Sarwar S 27/27 100 NO 
11 Moja L 
 
27/27 100 NO 
12 Solomon SD 
 
27/27 100 NO 
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Results of correlation between PRISMA percentage score in individual meta-
analysis and year of publication, number of authors, number of studies, number 
of patients and journal impact factor: For investigating the possible correlation 
between PRISMA %score in individual studies and other characteristics 
measured (year of publication, number of authors, number studies, number of 
patients, impact factor), we performed bivariate correlation in SPSS statistical 
package. The variables used were PRISMA percentage score and each one of: 
number of authors, number of studies, number of patients, year of publication 
and impact factor. The results are listed in Chart 1. 
 
Correlations between 
PRISMA %score and: 
Correlation 
coefficient 
(r) 
Pvalue Significance 
(Pvalue<0,05)  
Year of Publication 0,118 0,715 NO 
Number of Authors 0,258 0,418 NO 
Number of Studies 0,140 0,665 NO 
Number of Patients 0,385 0,216 NO 
Journal Impact Factor 0,792 0,002 YES 
Chart 1: Correlations Results 
 
 
SPSS Figure 4: Primary Correlation Results 
Because of Pvalue (=0,002) being beyond the limit of statistical significance and 
the correlation coefficient r (=0,792) being larger than 0,7 , we concluded that 
there is statistically significant positive strong correlation between PRISMA 
percentage score in individual meta-analyses and journal impact factor. The 
scatter dot diagram in Figure 3 presents visually the correlation. Linear 
regression was performed on this result, but the linearity was not established, as 
shown in SPSS Figure 5 (Pvalue=0,002 >0,001).  
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Figure 3: Scatter Dot Diagram JIF/%score 
 
SPSS Figure 5: Primary Linearity Results 
Results of multivariate analysis between High PRISMA score (≥24/27) MAs VS 
low PRISMA score MAs (≤23/27) in the mean values of: number of authors, 
number of studies, number of patients, year of publication and impact factor. We 
distinguished studies that possessed PRISMA score ≤23/27 and studies that 
possessed PRISMA score ≥24/27. We performed multivariate analysis by SPSS 
statistical package for comparing the MAs with PRISMA score ≤23/27 and the 
MAs with PRISMA score ≥24/27, as two separate values, and the mean values 
of: number of authors, number of studies, number of patients, year of publication 
and impact factor. These continuous variables are assumed to be dependent and 
thus, we tested the accumulated correlation between variables simultaneously on 
PRISMA score evaluation. For multivariate analysis, we performed a large 
amount of combinations between these continuous variables, and we display in 
Chart 2 the statistically significant results (Hotelling’s T2 Pvalue<0,05) of this 
analysis. 
 
Multivariate analysis of continuous variables 
between MAs with PRISMA score ≥24/27and 
MAs with PRISMA score ≤23/27 
Hotelling’s 
Trace 
Pvalue 
Significance  
Impact Factor and Number of studies 0,059 Borderline 
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Number of authors, Number of patients, Number of Studies, Year 
of Publication and Impact factor 
0,026 YES 
Number of authors, Number of Studies, Year of Publication and 
Impact Factor 
0,009 YES 
Number of studies, Number of Patients, Year of Publication and 
Impact Factor 
0,009 YES 
Year of Publication, Impact Factor and Number of studies 0,002 YES 
Year of Publication and Impact Factor 0,001 YES 
Chart 2: Multivariate Analysis 
 
We concluded that there is evidence of a significant difference in means for MAs 
with high PRISMA score ≥24/27 and MAs with lower PRISMA score ≤23/27 
taking account for variables as Number of authors, Number of patients, Number 
of Studies, Year of Publication and Impact factor of publication journal 
(Pvalue=0,026) simultaneously. The evidence is stronger when Year of 
Publication, Impact Factor and Number of studies are accumulated 
(Pvalue=0,002) and when Impact Factor and Publication Year are accumulated 
(Pvalue=0,001), as expected. 
Secondary outcomes 
Results of statistical difference of MAs with and without PRISMA endorsement in 
means of PRISMA percentage score: Five meta-analyses were conducted 
according to PRISMA guidance (Li S et al, Wang W et al, Kodjikian L et al, Si JK 
et al and Ueta T et al). So, PRISMA statement was claimed to be endorsed by 5 
out of 11 papers (45,4%) and by 5 out of 9 non-Cochrane MAs (55,5%). The 
mean PRISMA score in the above five MAs was 22,2/27. 
We tested the possible difference of MAs with PRISMA adherence and without 
PRISMA adherence in means of PRISMA percentage score. The normality test 
resulted in Pvalue=0,031 <0,05 and thus, we assume that our measurements do 
not follow normal distribution and the hypothesis for conducting a parametric test 
is not fulfilled. Non-parametric Mann-Whitney U test was performed. Statistical 
significance is not established in this outcome, as shown in SPSS Figure 6 
(Pvalue=0,322 >0,05). 
 
 
 
 
 
SPSS Figure 6: Secondary Results 
Results of multivariate analysis between PRISMA Endorsement and no PRISMA 
endorsement MAs in the mean values of: PRISMA percentage score, number of 
authors, number of studies, number of patients, year of publication and impact 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:09:38 EEST - 137.108.70.13
20 
 
UNIVERSITY OF THESSALY, September 2018                                                                                              
factor: We performed multivariate analysis by SPSS statistical package for 
comparing the MAs with PRISMA endorsement and MAs without PRISMA 
endorsement, as two separate values, and the mean values of: PRISMA %score 
in individual studies, number of authors, number of studies, number of patients, 
year of publication and impact factor. These variables are assumed to be 
dependent and thus, we tested the accumulated correlation between variables 
simultaneously on PRISMA endorsement. For multivariate analysis, we 
performed a large amount of combinations between these continuous variables, 
however, no results were statistically significant. As an implication for future 
evaluation, we present results of most promising combinations in Chart 3. 
 
Multivariate analysis of continuous variables 
between MAs with and without PRISMA 
Endorsement 
Hotelling’s 
Trace 
Pvalue 
Number of authors and Year of Publication 0,169 
Number of authors, Number of Studies and Year of Publication 0,181 
Number of authors, Number of Patients and Year of Publication 0,198 
Year of Publication, Impact Factor and %PRISMA score 0,211 
Year of Publication and Impact Factor 0,211 
Year of Publication, Impact Factor and Number of authors 0,223 
Year of Publication, Impact Factor, Number of authors and 
Number of Studies 
0,235 
Year of Publication and Number of Studies 0,243 
Year of Publication, Number of Studies and Impact Factor 0,244 
Chart 3: Multivariate Analysis 
 
 
Results of difference between MAs using Cochrane Handbook of Systematic 
Reviews of Interventions as a guidance tool for risk of bias assessment and MAs 
using Jadad score or author’s opinion in means of PRISMA percentage score: 
We tested the possible difference of MAs using the Cochrane Handbook of 
Systematic Reviews of Interventions VS MAs using Jadad score or author’s 
opinion in means of %PRISMA score measurements. The normality test resulted 
in Pvalue=0,001 <0,05 and thus, we assume that our measurements do not 
follow normal distribution and the hypothesis for conducting a parametric test is 
not fulfilled. Non-parametric Mann-Whitney U test was performed to detect a 
possible difference of these parameters. Statistical evidence was high 
(Pvalue=0,006), as presented in SPSS Figure 7. We concluded that there is 
statistical difference in PRISMA percentage score between MAs using the 
Cochrane Handbook of Systematic Reviews of Interventions for risk of bias 
assessment and MAs using only Jadad score or just author’s opinion on this 
topic.  
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SPSS Figure 7: Secondary Results 
Results of multivariate analysis between MAs using the Cochrane Handbook of 
Systematic Reviews of Interventions for risk of bias assessment and the MAs 
using Jadad score or author’s opinion in the mean values of: PRISMA 
percentage score, number of authors, number of studies, number of patients, 
year of publication and impact factor: We performed multivariate analysis by 
SPSS statistical package for comparing the MAs using the Cochrane Handbook 
of Systematic Reviews of Interventions for risk of bias assessment and the MAs 
using Jadad score or author’s opinion, as two separate values, in the mean 
values of: PRISMA percentage score, number of authors, number of studies, 
number of patients, year of publication and impact factor. For multivariate 
analysis, we performed a large amount of combinations between these 
continuous variables, and the statistically significant results (Hotelling’s T2 
Pvalue<0,05) of this analysis are presented in Chart 4. 
 
Multivariate analysis of continuous variables 
between MAs using  Cochrane Handbook of 
Systematic Reviews of Interventions for risk of 
bias assessment and the MAs using Jadad score 
or author’s opinion 
Hotelling’s 
Trace 
Pvalue 
Significance  
%PRISMA score, Number of authors, Number of Studies and Number 
of Patients, Impact Factor and Year of publication 0,021 YES 
%PRISMA score, Number of authors, Number of Studies and Number 
of Patients 
0,009 YES 
%PRISMA score, Number of Studies and Number of authors 0,003 YES 
Number of authors, Number of Studies 0,001 YES 
 Impact Factor, Number of Studies and %PRISMA score 0,000 YES 
 Impact Factor and %PRISMA score 0,000 YES 
Year of Publication, Impact Factor and %PRISMA score 0,000 YES 
Chart 4: Multivariate Analysis 
 
The results came up to our expectations. We concluded that there is evidence of 
a significant difference in means for MAs using the Cochrane Handbook of 
Systematic Reviews of Interventions and MAs using Jadad score or author’s 
opinion on risk of bias assessment taking account for variables as PRISMA 
%score, number of authors, number of patients, number of Studies, year of 
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Publication and impact factor of publication journal (Pvalue=0,021). The evidence 
is stronger when Year of Publication, Impact Factor and PRISMA percentage 
score are accumulated (Pvalue=0,000) and when Impact Factor and PRISMA 
percentage score are accumulated (Pvalue=0,000), as expected. 
Results of chi-square test: In order to compare the proportions of MAs with 
PRISMA score ≤23/27and the MAs with PRISMA score ≥24/27 that used either 
Cochrane Handbook of Systematic Reviews of Interventions or Jadad 
score/author’s opinion, we performed chi-square test. The odds ratio of this 
difference (OR=0,2) was not statistically significant {95%CI (0,035, 1,154)}, as 
displayed in SPSS Figure 8. Therefore and least expected, there is not a 
statistically significant correlation between the proportion of high score MAs and 
the usage of guidance tool.   
 
SPSS Figure 8: Chi-square test 
Discussion  
The median compliance in this assessment was 16/27 items (59,2%), which is 
relatively consistent in comparison with previous studies that investigate the 
reporting quality of reviews in ophthalmology (33). Nevertheless, this consistency 
is considered to be poorer than previous studies on reporting quality in other 
fields (34-36). Cochrane Systematic Reviews met all criteria of impeccable 
reporting and more than half of 9 remaining Meta-analyses achieved more than 
80% in total scoring (Nguyen CL, Li S, Kodjikian L, Ueta T, Su Y). This 
achievement may reflect the fact that widespread compliance with the PRISMA 
checklist by authors has improved over the years. Furthermore, this achievement 
may indicate that widespread compliance by journal editors and reviewers, 
making PRISMA adherence mandatory for acceptance, has benefited the 
reporting quality of articles. Regardless of Cochrane SRs, since they significantly 
raise the compliance rates in our study, three items with approximate compliance 
of 20% determine the poor reporting of protocol and registration description, 
electronic search strategy clarification and funding source clarification. The lack 
of adequate reporting of protocol and registration in our estimations is highlighted 
in previous investigational work on ophthalmology (33) and other fields of interest 
(34,36-39). Moreover, four PRISMA items with approximate compliance of 50% 
obviously identify the problematic reporting of risk of bias methodology and 
findings description, evidence in accord with previous findings (33,36-39). 
Scrutinized reporting of risk of bias methods and outcome-level assessment is 
weighted of crucial value and plays a pivotal role in overall reporting quality of a 
meta-analysis. Detailed risk of bias estimates are the most valued arrows in 
healthcare professionals’ quiver when clinical decisions are based on Evidence-
Based Medicine. We believe that the most prominent strength in this task lies in 
the strict inclusion of meta-analysis of RCTs. Moreover, our task strength lies in 
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the statistical handling of data investigating several parameters. Because 
PRISMA statement appeals to all medical specialties, specific details added in 
reporting of each medical specialty should also be concerned. In ophthalmology, 
specific methodological issues include presentation of data from each eye as a 
challenge for sufficient reporting quality (33). Anticorruption of unawareness of 
PRISMA reporting principles and aliveness aiming for widespread explanation of 
PRISMA items will undeniably result in compliance improvement (40).     
The main limitation of this study is that the compliance results in sixteen PRISMA 
items achieved the highest score (100%) indicating a scoring generosity aspect. 
However, our scoring was strict consistently with previous studies for risk of bias 
assessment related items. To our judgment, if scoring is generous on behalf of 
authors for specific items (e.g. objectives) and strict for methodology and 
outcomes of risk of bias evaluations, the weighted importance of these 
evaluations is more obviously revealed in scoring results. Another limitation is 
that search results included only published meta-analyses, an indication that 
publication bias may affect this assessment’s outcomes. The inclusion of three 
Cochrane SRs may eliminate this effect due to unpublished RCTs entry. 
To summarize, our assessment proved the significance of incorporating 
Cochrane Systematic Reviews by raising PRISMA ITEMS percentage score. 
Another primary finding is the strong positive association of PRISMA percentage 
score of individual meta-analysis with Journal Impact Factor (Pearson 
correlation=0,792, P=0,002). The last of primary outcomes is the association of 
high PRISMA score (≥24/27) MAs VS low PRISMA score (≤23/27) MAs with the 
combination of simultaneous evidence from certain characteristics of meta-
analysis (Number of authors, Number of patients, Number of Studies, Year of 
Publication and Impact factor) (P=0,026). The highest evidence was produced of 
the combination of Journal Impact Factor and Year of publication (P=0,001) 
implicating their accumulated strong correlation to high reporting quality. 
Secondary findings in this work were also important. Multivariate analysis 
showed that the usage of a standardized guidance tool, as the Cochrane 
Handbook of Systematic Reviews of Interventions compared to other 
methodology used (Jadad score/author’s opinion), is associated to the 
combination of evidence from PRISMA percentage score, Number of authors, 
Number of patients, Number of Studies, Year of Publication and Impact factor 
(P=0,021). Finally, our assessment identified the difference in mean PRISMA 
percentage score between MAs using the Cochrane Handbook of Systematic 
Reviews of Interventions for risk of bias assessment in their analysis and MAs 
using only Jadad score or just author’s opinion on this topic (P=0,006).  
Conclusions  
The reporting quality of ophthalmological Meta-analyses in exudative AMD 
treatment and safety profile was generally optimal. Further improvement is 
required, especially in describing the review protocol and registration, electronic 
search strategy, funding sources, and risk of bias methodology and evaluation. 
Universal endorsement of PRISMA statement by journals is recommended at the 
time of journal submission of articles. The key role of several characteristics of 
meta-analyses (e.g. journal impact factor) substantially affects their reporting 
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quality. We strongly suggest that adherence to PRISMA is mandatory to fulfill all 
criteria as vital elements of reporting quality, although we suggest that much 
weight should be given to risk of bias procedure and outcomes.  
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